Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 4/2014

01-05-2014 | Review

Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis

Auteurs: Stefan G. Hofmann, Jade Q. Wu, Hannah Boettcher, Jamie Sturm

Gepubliceerd in: Quality of Life Research | Uitgave 4/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Pharmacotherapy is an effective treatment for anxiety disorders, but its effects on quality of life (QOL) have not been examined systematically. Our objective was to conduct an effect size analysis of pharmacological interventions on QOL outcomes in patients with DSM-IV anxiety disorders.

Methods

Manual and electronic searches using PubMed, PsycINFO, and the Cochrane Library were conducted for records from the first available date through May 1, 2013 for trials of pharmacological interventions in patients with anxiety disorders, which had measures of QOL before and after treatment. Of 1,865 entries, 93 studies were identified as potentially relevant and 32 met inclusion criteria, of which results were examined from 22 studies reporting 27 distinct pharmacological trials, representing data from 4,344 anxiety disorder patients. Data were extracted independently by multiple observers to estimate within-group and placebo-controlled random effects of the treatment changes on QOL. We hypothesized that pharmacotherapy improves QOL, which is associated with improvement in anxiety symptoms.

Results

Pharmacological interventions effectively improved QOL from before to after treatment (Hedges’ g = 0.59), although the controlled effect size is smaller among those trials with placebo interventions (Hedges’ g = 0.32). These effect sizes were robust, increased with publication year, and increased with reductions in anxiety symptoms.

Conclusions

Pharmacological therapy is effective for improving QOL in anxiety disorders, and larger symptom reductions are associated with greater improvement in QOL.

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Literatuur
1.
go back to reference Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627. PubMedCentralPubMedCrossRef Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627. PubMedCentralPubMedCrossRef
2.
go back to reference DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R., & Harwood, H. J. (1996). Economic costs of anxiety disorders. Anxiety, 2(4), 167–172. PubMedCrossRef DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R., & Harwood, H. J. (1996). Economic costs of anxiety disorders. Anxiety, 2(4), 167–172. PubMedCrossRef
3.
go back to reference Cramer, V., Torgersen, S., & Kringlen, E. (2005). Quality of life and anxiety disorders: A population study. Journal of Nervous and Mental Disease, 193(3), 196–202. PubMedCrossRef Cramer, V., Torgersen, S., & Kringlen, E. (2005). Quality of life and anxiety disorders: A population study. Journal of Nervous and Mental Disease, 193(3), 196–202. PubMedCrossRef
4.
go back to reference Mendlowicz, M. V., & Stein, M. B. (2000). Quality of life in individuals with anxiety disorders. American Journal of Psychiatry, 157(5), 669–682. PubMedCrossRef Mendlowicz, M. V., & Stein, M. B. (2000). Quality of life in individuals with anxiety disorders. American Journal of Psychiatry, 157(5), 669–682. PubMedCrossRef
5.
go back to reference Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27(5), 572–581. PubMedCrossRef Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27(5), 572–581. PubMedCrossRef
6.
go back to reference Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005). Quality-of-life impairment in depressive and anxiety disorders. American Journal of Psychiatry, 162(6), 1171–1178. PubMedCrossRef Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005). Quality-of-life impairment in depressive and anxiety disorders. American Journal of Psychiatry, 162(6), 1171–1178. PubMedCrossRef
7.
go back to reference Spitzer, R. L., Kroenke, K., Linzer, M., Hahn, S. R., Williams, J. B., Brody, D., et al. (1995). Health-related quality of life in primary care patients with mental disorders. Journal of the American Medical Association, 274(19), 1511–1517. PubMedCrossRef Spitzer, R. L., Kroenke, K., Linzer, M., Hahn, S. R., Williams, J. B., Brody, D., et al. (1995). Health-related quality of life in primary care patients with mental disorders. Journal of the American Medical Association, 274(19), 1511–1517. PubMedCrossRef
8.
go back to reference Sherbourne, C. D., Wells, K. B., & Judd, L. L. (1996). Functioning and well-being of patients with panic disorder. American Journal of Psychiatry, 153(2), 213–218. PubMed Sherbourne, C. D., Wells, K. B., & Judd, L. L. (1996). Functioning and well-being of patients with panic disorder. American Journal of Psychiatry, 153(2), 213–218. PubMed
9.
go back to reference Angermeyer, M. C., & Kilian, R. (2006). Theoretical models of quality of life for mental disorders. In H. Katschnig, H. Freeman, & N. Sartorius (Eds.), Quality of life in mental disorders (2nd ed.). Chichester: Wiley. Angermeyer, M. C., & Kilian, R. (2006). Theoretical models of quality of life for mental disorders. In H. Katschnig, H. Freeman, & N. Sartorius (Eds.), Quality of life in mental disorders (2nd ed.). Chichester: Wiley.
10.
go back to reference Gyani, A., Shafran, R., Layard, R., & Clark, D. M. (2013). Enhancing recovery rates: Lessons from year one of IAPT. Behaviour Research and Therapy, 51(9), 597–606. PubMedCentralPubMedCrossRef Gyani, A., Shafran, R., Layard, R., & Clark, D. M. (2013). Enhancing recovery rates: Lessons from year one of IAPT. Behaviour Research and Therapy, 51(9), 597–606. PubMedCentralPubMedCrossRef
11.
go back to reference Frisch, M. B. (1998). Quality of life therapy and assessment in health care. Clinical Psychology: Science and Practice, 5(1), 19–40. Frisch, M. B. (1998). Quality of life therapy and assessment in health care. Clinical Psychology: Science and Practice, 5(1), 19–40.
12.
go back to reference Gladis, M. M., Gosch, E. A., Dishuk, N. M., & Crits-Christoph, P. (1999). Quality of life: Expanding the scope of clinical significance. Journal of Consulting and Clinical Psychology, 67(3), 320–331. PubMedCrossRef Gladis, M. M., Gosch, E. A., Dishuk, N. M., & Crits-Christoph, P. (1999). Quality of life: Expanding the scope of clinical significance. Journal of Consulting and Clinical Psychology, 67(3), 320–331. PubMedCrossRef
13.
go back to reference Cohen, J. (1968). Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. Psychological Bulletin, 70(4), 213. PubMedCrossRef Cohen, J. (1968). Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. Psychological Bulletin, 70(4), 213. PubMedCrossRef
14.
go back to reference Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17(1), 1–12. PubMedCrossRef Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17(1), 1–12. PubMedCrossRef
15.
go back to reference Rosenthal, R. (1991). Meta- analytic procedures for social research (revised ed.). Thousand Oaks, CA: Publications Inc. Rosenthal, R. (1991). Meta- analytic procedures for social research (revised ed.). Thousand Oaks, CA: Publications Inc.
16.
go back to reference Rosenthal, R., & Rubin, D. B. (1988). [Selection models and the file drawer problem]: Comment: Assumptions and procedures in the file drawer problem. Statistical Science, 3(1), 120–125. CrossRef Rosenthal, R., & Rubin, D. B. (1988). [Selection models and the file drawer problem]: Comment: Assumptions and procedures in the file drawer problem. Statistical Science, 3(1), 120–125. CrossRef
19.
go back to reference Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. New York: Academic Press. Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. New York: Academic Press.
20.
go back to reference Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum.
21.
go back to reference Rosenthal, R. (1993). Meta-analytic procedures for social research. Newbury Park, CA: Sage Publications. Rosenthal, R. (1993). Meta-analytic procedures for social research. Newbury Park, CA: Sage Publications.
22.
go back to reference Hedges, L. V., & Vevea, J. L. (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods, 3(4), 486–504. CrossRef Hedges, L. V., & Vevea, J. L. (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods, 3(4), 486–504. CrossRef
23.
go back to reference Moses, L. E., Mosteller, F., & Beuhler, J. H. (2002). Comparing results of large clinical trials to those of meta-analyses. Statistics in Medicine, 21(6), 793–800. PubMedCrossRef Moses, L. E., Mosteller, F., & Beuhler, J. H. (2002). Comparing results of large clinical trials to those of meta-analyses. Statistics in Medicine, 21(6), 793–800. PubMedCrossRef
24.
go back to reference Borenstein, M., Hedges, L. V., Higgins, J., & Rothstein, H. (2005). Comprehensive meta-analysis, version 2. Englewood, NJ: Biostat Inc. Borenstein, M., Hedges, L. V., Higgins, J., & Rothstein, H. (2005). Comprehensive meta-analysis, version 2. Englewood, NJ: Biostat Inc.
25.
go back to reference Ball, S. G., Kuhn, A., Wall, D., Shekhar, A., & Goddard, A. W. (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: A double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry, 66(1), 94–99. PubMedCrossRef Ball, S. G., Kuhn, A., Wall, D., Shekhar, A., & Goddard, A. W. (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: A double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry, 66(1), 94–99. PubMedCrossRef
26.
go back to reference Beşiroğlu, L., Uğuz, F., Yilmaz, E., Ağargün, M., Aşkin, R., & Aydin, A. (2008). Psychopharmacological treatment and quality of life in obsessive compulsive disorder. Turkish Journal of Psychiatry, 19(1), 38. PubMed Beşiroğlu, L., Uğuz, F., Yilmaz, E., Ağargün, M., Aşkin, R., & Aydin, A. (2008). Psychopharmacological treatment and quality of life in obsessive compulsive disorder. Turkish Journal of Psychiatry, 19(1), 38. PubMed
27.
go back to reference Blank, S., Lenze, E. J., Mulsant, B. H., Dew, M. A., Karp, J. F., Shear, M. K., et al. (2006). Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. Journal of Clinical Psychiatry, 67(3), 468–472. PubMedCrossRef Blank, S., Lenze, E. J., Mulsant, B. H., Dew, M. A., Karp, J. F., Shear, M. K., et al. (2006). Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. Journal of Clinical Psychiatry, 67(3), 468–472. PubMedCrossRef
28.
go back to reference Blaya, C., Seganfredo, A. C., Dornelles, M., Torres, M., Paludo, A., Heldt, E., et al. (2007). The efficacy of milnacipran in panic disorder: An open trial. International Clinical Psychopharmacology, 22(3), 153. PubMedCrossRef Blaya, C., Seganfredo, A. C., Dornelles, M., Torres, M., Paludo, A., Heldt, E., et al. (2007). The efficacy of milnacipran in panic disorder: An open trial. International Clinical Psychopharmacology, 22(3), 153. PubMedCrossRef
29.
go back to reference Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., et al. (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. Journal of the American Medical Association, 283(14), 1837–1844. PubMedCrossRef Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., et al. (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. Journal of the American Medical Association, 283(14), 1837–1844. PubMedCrossRef
30.
go back to reference Bruce, L. C., Heimberg, R. G., Blanco, C., Schneier, F. R., & Liebowitz, M. R. (2012). Childhood maltreatment and social anxiety disorder: Implications for symptom severity and response to pharmacotherapy. Depression and Anxiety, 29(2), 132–139. PubMedCentralCrossRef Bruce, L. C., Heimberg, R. G., Blanco, C., Schneier, F. R., & Liebowitz, M. R. (2012). Childhood maltreatment and social anxiety disorder: Implications for symptom severity and response to pharmacotherapy. Depression and Anxiety, 29(2), 132–139. PubMedCentralCrossRef
31.
go back to reference Davidson, J. R., Bose, A., & Wang, Q. (2005). Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry, 66(11), 1441. PubMedCrossRef Davidson, J. R., Bose, A., & Wang, Q. (2005). Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry, 66(11), 1441. PubMedCrossRef
32.
go back to reference Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., et al. (2006). Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial. Archives of General Psychiatry, 63(10), 1158. PubMedCrossRef Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., et al. (2006). Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial. Archives of General Psychiatry, 63(10), 1158. PubMedCrossRef
33.
go back to reference Dougherty, D. D., Jameson, M., Deckersbach, T., Loh, R., Thompson-Hollands, J., Jenike, M., et al. (2009). Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorder. International Clinical Psychopharmacology, 24(6), 306–311. PubMedCrossRef Dougherty, D. D., Jameson, M., Deckersbach, T., Loh, R., Thompson-Hollands, J., Jenike, M., et al. (2009). Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorder. International Clinical Psychopharmacology, 24(6), 306–311. PubMedCrossRef
34.
go back to reference Francois, C., Montgomery, S. A., Despiegel, N., Roiz, J., & Auguier, P. (2008). Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention with generalised anxiety disorder. International Journal of Clinical Practice, 62(11), 1693–1702. PubMedCentralPubMedCrossRef Francois, C., Montgomery, S. A., Despiegel, N., Roiz, J., & Auguier, P. (2008). Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention with generalised anxiety disorder. International Journal of Clinical Practice, 62(11), 1693–1702. PubMedCentralPubMedCrossRef
35.
go back to reference Koran, L. M., Bromberg, D., Hornfeldt, C. S., Shepski, J. C., Wang, S., & Hollander, E. (2010). Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Comprehensive Psychiatry, 51(4), 373–379. PubMedCrossRef Koran, L. M., Bromberg, D., Hornfeldt, C. S., Shepski, J. C., Wang, S., & Hollander, E. (2010). Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Comprehensive Psychiatry, 51(4), 373–379. PubMedCrossRef
36.
go back to reference Liebowitz, M. R., DeMartinis, N. A., Weihs, K., Londborg, P. D., Smith, W. T., Chung, H., et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 64(7), 785–792. PubMedCrossRef Liebowitz, M. R., DeMartinis, N. A., Weihs, K., Londborg, P. D., Smith, W. T., Chung, H., et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 64(7), 785–792. PubMedCrossRef
37.
go back to reference Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., et al. (2011). Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. Journal of the American Medical Association, 306(5), 493. PubMedCrossRef Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., et al. (2011). Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. Journal of the American Medical Association, 306(5), 493. PubMedCrossRef
38.
go back to reference McRae, A. L., Brady, K. T., Mellman, T. A., Sonne, S. C., Killeen, T. K., Timmerman, M. A., et al. (2004). Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety, 19(3), 190–196. PubMedCrossRef McRae, A. L., Brady, K. T., Mellman, T. A., Sonne, S. C., Killeen, T. K., Timmerman, M. A., et al. (2004). Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety, 19(3), 190–196. PubMedCrossRef
39.
go back to reference Menza, M. A., Dobkin, R. D., & Marin, H. (2007). An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. Journal of Clinical Psychopharmacology, 27(2), 207–210. PubMedCrossRef Menza, M. A., Dobkin, R. D., & Marin, H. (2007). An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. Journal of Clinical Psychopharmacology, 27(2), 207–210. PubMedCrossRef
40.
go back to reference Muehlbacher, M., Nickel, M. K., Nickel, C., Kettler, C., Lahmann, C., Gil, F. P., et al. (2005). Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 25(6), 580–583. PubMedCrossRef Muehlbacher, M., Nickel, M. K., Nickel, C., Kettler, C., Lahmann, C., Gil, F. P., et al. (2005). Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 25(6), 580–583. PubMedCrossRef
41.
go back to reference Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., et al. (2008). Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment. Journal of Psychiatric Research, 42(12), 1042. PubMedCrossRef Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., et al. (2008). Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment. Journal of Psychiatric Research, 42(12), 1042. PubMedCrossRef
42.
go back to reference Simon, N. M., Kaufman, R. E., Hoge, E. A., Worthington, J. J., Herlands, N. N., Owens, M. E., et al. (2009). Open-label support for duloxetine for the treatment of panic disorder. CNS Neuroscience & Therapeutics, 15(1), 19–23. CrossRef Simon, N. M., Kaufman, R. E., Hoge, E. A., Worthington, J. J., Herlands, N. N., Owens, M. E., et al. (2009). Open-label support for duloxetine for the treatment of panic disorder. CNS Neuroscience & Therapeutics, 15(1), 19–23. CrossRef
43.
go back to reference Stahl, S. M., Gergel, I., & Li, D. (2003). Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 64(11), 1322. PubMedCrossRef Stahl, S. M., Gergel, I., & Li, D. (2003). Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 64(11), 1322. PubMedCrossRef
44.
go back to reference Tenney, N. H., Denys, D. A., van Megen, H. J., Glas, G., & Westenberg, H. G. (2003). Effect of a pharmacological intervention on quality of life in patients with obsessive–compulsive disorder. International Clinical Psychopharmacology, 18(1), 29–33. PubMedCrossRef Tenney, N. H., Denys, D. A., van Megen, H. J., Glas, G., & Westenberg, H. G. (2003). Effect of a pharmacological intervention on quality of life in patients with obsessive–compulsive disorder. International Clinical Psychopharmacology, 18(1), 29–33. PubMedCrossRef
45.
go back to reference van Apeldoorn, F. J., Timmerman, M. E., Mersch, P. P., van Hout, W. J., Visser, S., van Dyck, R., et al. (2010). A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up. Journal of Clinical Psychiatry, 71(5), 574. PubMedCrossRef van Apeldoorn, F. J., Timmerman, M. E., Mersch, P. P., van Hout, W. J., Visser, S., van Dyck, R., et al. (2010). A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up. Journal of Clinical Psychiatry, 71(5), 574. PubMedCrossRef
46.
go back to reference Zhang, J., Hongbing, X., & Zhiqing, C. (2013). Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder. Experimental and Therapeutic Medicine, 5(3), 840. PubMedCentralPubMed Zhang, J., Hongbing, X., & Zhiqing, C. (2013). Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder. Experimental and Therapeutic Medicine, 5(3), 840. PubMedCentralPubMed
47.
go back to reference Frisch, M. B., Clark, M. P., Rouse, S. V., Rudd, M. D., Paweleck, J. K., Greenstone, A., et al. (2005). Predictive and treatment validity of life satisfaction and the Quality of Life Inventory. Assessment, 12(1), 66–78. PubMedCrossRef Frisch, M. B., Clark, M. P., Rouse, S. V., Rudd, M. D., Paweleck, J. K., Greenstone, A., et al. (2005). Predictive and treatment validity of life satisfaction and the Quality of Life Inventory. Assessment, 12(1), 66–78. PubMedCrossRef
48.
go back to reference WHOQOL Group. (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological Medicine, 28(3), 551–558. CrossRef WHOQOL Group. (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological Medicine, 28(3), 551–558. CrossRef
49.
go back to reference Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321–326. PubMed Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321–326. PubMed
50.
go back to reference Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(20), 22–33. PubMed Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(20), 22–33. PubMed
51.
go back to reference EuroQol Group. (1990). EuroQol—A new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef EuroQol Group. (1990). EuroQol—A new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef
52.
go back to reference Jenkinson, C., Layte, R., & Lawrence, K. (1997). Development and testing of the Medical Outcomes Study 36-item short form health survey summary scale scores in the United Kingdom: Results from a large-scale survey and a clinical trial. Medical Care, 35(4), 410–416. PubMedCrossRef Jenkinson, C., Layte, R., & Lawrence, K. (1997). Development and testing of the Medical Outcomes Study 36-item short form health survey summary scale scores in the United Kingdom: Results from a large-scale survey and a clinical trial. Medical Care, 35(4), 410–416. PubMedCrossRef
53.
go back to reference Ware, J. E., Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. PubMedCrossRef Ware, J. E., Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. PubMedCrossRef
54.
go back to reference Hay, R. D., Sherbourne, C. D., & Mazel, R. M. (1993). The RAND 36-Item Health Survey 1.0. Health Economics, 2(3), 217–227. CrossRef Hay, R. D., Sherbourne, C. D., & Mazel, R. M. (1993). The RAND 36-Item Health Survey 1.0. Health Economics, 2(3), 217–227. CrossRef
55.
go back to reference Oliver, J. P. J., Huxley, P., Bridges, K., & Mohamad, H. (1996). Quality of life and mental health services. London: Routledge. Oliver, J. P. J., Huxley, P., Bridges, K., & Mohamad, H. (1996). Quality of life and mental health services. London: Routledge.
56.
go back to reference König, H. H., Born, A., Günther, O., Matschinger, H., Heinrich, S., Riedel-Heller, S. G., et al. (2010). Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health and Quality of Life Outcomes, 8, 47. PubMedCentralPubMedCrossRef König, H. H., Born, A., Günther, O., Matschinger, H., Heinrich, S., Riedel-Heller, S. G., et al. (2010). Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health and Quality of Life Outcomes, 8, 47. PubMedCentralPubMedCrossRef
57.
go back to reference Wyrwich, K., Harnam, N., Revicki, D. A., Locklear, J. C., Svedsäter, H., & Endicott, J. (2009). Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology, 24(6), 289–295. PubMedCrossRef Wyrwich, K., Harnam, N., Revicki, D. A., Locklear, J. C., Svedsäter, H., & Endicott, J. (2009). Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology, 24(6), 289–295. PubMedCrossRef
58.
go back to reference McAlinden, N. M., & Oei, T. P. (2006). Validation of the Quality of Life Inventory for patients with anxiety and depression. Comprehensive Psychiatry, 47(4), 307–314. PubMedCrossRef McAlinden, N. M., & Oei, T. P. (2006). Validation of the Quality of Life Inventory for patients with anxiety and depression. Comprehensive Psychiatry, 47(4), 307–314. PubMedCrossRef
59.
go back to reference Hambrick, J. P., Turk, C. L., Heimberg, R. G., Schneier, F. R., & Liebowitz, M. R. (2004). Psychometric properties of disability measures among patients with social anxiety disorder. Journal of Anxiety Disorders, 18(6), 825–839. PubMedCrossRef Hambrick, J. P., Turk, C. L., Heimberg, R. G., Schneier, F. R., & Liebowitz, M. R. (2004). Psychometric properties of disability measures among patients with social anxiety disorder. Journal of Anxiety Disorders, 18(6), 825–839. PubMedCrossRef
60.
go back to reference Lehrer, J. (2010). The decline effect and the scientific method: The truth wears off. New Yorker, p. 52. Lehrer, J. (2010). The decline effect and the scientific method: The truth wears off. New Yorker, p. 52.
61.
go back to reference Schooler, J. (2011). Cosmic habituation [Radio broadcast]. In E. Horne (Producer), Radiolab. New York: WNYC. Schooler, J. (2011). Cosmic habituation [Radio broadcast]. In E. Horne (Producer), Radiolab. New York: WNYC.
63.
go back to reference Hofmann, S. G., Asnaani, A., Vonk, J. J., Sawyer, A. T., & Fang, A. (2012). The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognitive Therapy and Research, 36(5), 427–440. PubMedCentralPubMedCrossRef Hofmann, S. G., Asnaani, A., Vonk, J. J., Sawyer, A. T., & Fang, A. (2012). The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognitive Therapy and Research, 36(5), 427–440. PubMedCentralPubMedCrossRef
64.
go back to reference Safren, S. A., Heimberg, R. G., Brown, E. G., & Holle, C. (1997). Quality of life in patients with social phobia. Depression and Anxiety, 4(3), 126–133. CrossRef Safren, S. A., Heimberg, R. G., Brown, E. G., & Holle, C. (1997). Quality of life in patients with social phobia. Depression and Anxiety, 4(3), 126–133. CrossRef
65.
go back to reference Telch, M. J., Schmidt, N. B., Jaimez, T. L., Jacquin, K. M., & Harrington, P. J. (1995). Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. Journal of Consulting and Clinical Psychology, 63(5), 823–830. PubMedCrossRef Telch, M. J., Schmidt, N. B., Jaimez, T. L., Jacquin, K. M., & Harrington, P. J. (1995). Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. Journal of Consulting and Clinical Psychology, 63(5), 823–830. PubMedCrossRef
Metagegevens
Titel
Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis
Auteurs
Stefan G. Hofmann
Jade Q. Wu
Hannah Boettcher
Jamie Sturm
Publicatiedatum
01-05-2014
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0573-8